Начало・Списък с акции・Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals Inc

Отворен

СекторЗдравеопазване

2.48 2.06

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.38

Максимум

2.48

Ключови измерители
By Trading Economics
Приходи	171M 123M
EPS	-0.15
Служители	202
EBITDA	179M 134M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+289.34% upside

Дивиденти
By Acuity
Следващи печалби	4.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-147M 250M
Предишно отваряне	0.42
Предишно затваряне	2.48

Rocket Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

30.10.2026 г., 19:53 ч. UTC

Rocket Pharmaceuticals, Inc. shares fell sharply after pulling back from an early session high, remaining above its 20-day moving average.

29.10.2026 г., 20:07 ч. UTC

Rocket Pharmaceuticals, Inc. shares declined, pulling back from an earlier peak.

28.10.2026 г., 22:21 ч. UTC

Rocket Pharmaceuticals, Inc. shares are lower in after-market trading, reversing earlier gains to reach their lowest point of the day.

27.10.2026 г., 20:01 ч. UTC

Rocket Pharmaceuticals, Inc. shares are up sharply, showing strong momentum with a peak return exceeding 10% since Monday's close.

26.10.2026 г., 20:07 ч. UTC

Rocket Pharmaceuticals Inc shares are declining, having reached a session low earlier before recovering slightly, but remain below the 20-day moving average.

23.10.2026 г., 20:07 ч. UTC

Rocket Pharmaceuticals Inc shares are declining amid a broadly lower market, influenced by mixed economic indicators and rising oil prices raising inflation concerns.

22.10.2026 г., 20:07 ч. UTC

Rocket Pharmaceuticals Inc shares are trading sharply higher, rebounding from a recent decline, as the broader market experiences significant upward movement.

21.10.2026 г., 22:21 ч. UTC

Rocket Pharmaceuticals Inc. advanced sharply in after-market trading, closing at its peak.

20.10.2026 г., 20:21 ч. UTC

Rocket Pharmaceuticals Inc gained sharply in after-market trading, rising since Tuesday's close.

19.10.2026 г., 20:07 ч. UTC

Correlated Moves

Rocket Pharmaceuticals shares are higher, supported by positive clinical trial results in the biotech sector, alongside gains in the SPDR S&P Biotech ETF.

16.10.2026 г., 21:01 ч. UTC

Rocket Pharmaceuticals Inc shares advanced in after-market hours on Friday.

15.10.2026 г., 20:02 ч. UTC

Rocket Pharmaceuticals Inc is trading sharply higher, reversing a recent trend of declines after closing lower in each of the previous four sessions.

13.10.2026 г., 20:01 ч. UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend amid broader market weakness, remaining well below their 20-day moving average.

12.10.2026 г., 20:06 ч. UTC

Rocket Pharmaceuticals Inc shares are declining, continuing a downward trend since Friday, finishing near session lows and significantly below its 20-day moving average.

9.10.2026 г., 21:10 ч. UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, showing a notable increase since Friday's close while remaining near the lower end of its one-month range.

8.10.2026 г., 23:10 ч. UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, moving up since Thursday's close despite pulling back from an earlier peak.

7.10.2026 г., 20:07 ч. UTC

Social Media

News

Rocket Pharmaceuticals' gene therapy candidate RP-A501 shows promising initial results; shares are higher since Tuesday, despite earlier intraday weakness.

6.10.2026 г., 22:01 ч. UTC

News

Rocket Pharmaceuticals secures a $150 million credit facility with Hercules Capital to bolster its financial position and support its Phase 2 study of RP-A501.

5.10.2026 г., 20:06 ч. UTC

Rocket Pharmaceuticals Inc is advancing amid a broader market recovery, despite experiencing a significant decline over the past month and remaining near its recent lows.

2.10.2026 г., 19:45 ч. UTC

Rocket Pharmaceuticals Inc shares fell sharply, continuing a downward trend since Thursday and remaining significantly below its 20-day moving average.

1.10.2026 г., 21:01 ч. UTC

Rocket Pharmaceuticals Inc advanced in after-market trading on Thursday, recovering sharply from earlier losses amid broader market challenges.

30.09.2026 г., 20:07 ч. UTC

Rocket Pharmaceuticals Inc is gaining in today's trading session, advancing since Tuesday's close, despite a pullback from earlier session highs.

29.09.2026 г., 23:01 ч. UTC

Rocket Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close, despite a significant decline over the past month.

28.09.2026 г., 23:26 ч. UTC

Rocket Pharmaceuticals Inc gained in after-market hours on Monday, recovering from earlier losses, though it remains significantly lower compared to last month's close.

25.09.2026 г., 23:56 ч. UTC

Rocket Pharmaceuticals Inc is advancing in after-market trading, gaining significantly since Friday's close after a recent decline over the past month.

24.09.2026 г., 20:01 ч. UTC

Rocket Pharmaceuticals Inc shares fell sharply, reaching their lowest point of the day and remaining well below the 20-day moving average.

23.09.2026 г., 23:46 ч. UTC

Rocket Pharmaceuticals Inc saw an increase in after-market trading, recovering from an earlier session dip and advancing higher since Wednesday's close.

22.09.2026 г., 23:21 ч. UTC

Rocket Pharmaceuticals Inc is seeing a modest increase in after-market trading, building on Tuesday's close, although it remains below its 20-day moving average.

21.09.2026 г., 22:06 ч. UTC

Advanced modestly in after-market trading despite economic growth concerns.

18.09.2026 г., 22:56 ч. UTC

Rocket Pharmaceuticals Inc is trading higher in after-market hours, maintaining an upward trend since Friday's close despite being below its 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

Rocket Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

289.34% нагоре

12-месечна прогноза

Среден 9.5 USD 289.34%

Висок 15 USD

Нисък 4 USD

Според 11 анализатори от Wall Street, предложили 12-месечна ценова цел за Rocket Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

11 ratings

Купи

Задържане

Продай

Според 11 анализатори, дали борсови рейтинги на Rocket Pharmaceuticals Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.